The tariff classification of Methotrexate (CAS-59-05-2), imported in bulk form, from China
Issued October 27, 2003 by U.S. Customs and Border Protection.
Tariff classification
HTS codes: 2933.59.5300
Headings: 2933
Product description
The subject product, Methotrexate, is an antimetabolite used in the treatment of certain neoplastic diseases, severe psoriasis, and adult rheumatoid arthritis.
CBP rationale
The applicable subheading for Methotrexate, imported in bulk form, will be 2933.59.5300, Harmonized Tariff Schedule of the United States (HTS), which provides for “Heterocyclic compounds with nitrogen hetero-atom(s) only: Compounds containing a pyrimidine ring (whether or not hydrogenated) or piperazine ring in the structure: Other: Drugs: Aromatic or modified aromatic: Other.
Full text
NY J89958 October 27, 2003 CLA-2-29:RR:NC:2:238 J89958 CATEGORY: Classification TARIFF NO.: 2933.59.5300 Mr. Joseph J. Chivini Austin Chemical Company, Inc. 1565 Barclay Boulevard Buffalo Grove, IL 60089 RE: The tariff classification of Methotrexate (CAS-59-05-2), imported in bulk form, from China Dear Mr. Chivini: In your letter dated September 26, 2003, you requested a tariff classification ruling. The subject product, Methotrexate, is an antimetabolite used in the treatment of certain neoplastic diseases, severe psoriasis, and adult rheumatoid arthritis. The applicable subheading for Methotrexate, imported in bulk form, will be 2933.59.5300, Harmonized Tariff Schedule of the United States (HTS), which provides for “Heterocyclic compounds with nitrogen hetero-atom(s) only: Compounds containing a pyrimidine ring (whether or not hydrogenated) or piperazine ring in the structure: Other: Drugs: Aromatic or modified aromatic: Other.” Pursuant to General Note 13, HTS, the rate of duty will be free. This merchandise may be subject to the requirements of the Federal Food, Drug, and Cosmetic Act, which is administered by the U.S. Food and Drug Administration. You may contact them at 5600 Fishers Lane, Rockville, Maryland 20857, telephone number 301-443-1544. This ruling is being issued under the provisions of Part 177 of the Customs Regulations (19 C.F.R. 177). A copy of the ruling or the control number indicated above should be provided with the entry documents filed at the time this merchandise is imported. If you have any questions regarding the ruling, contact National Import Specialist Harvey Kuperstein at 646-733-3033. Sincerely, Robert B. Swierupski Director, National Commodity Specialist Division
More rulings on the same tariff codes
The tariff classification of Ensifentrine (CAS No. 1884461-72-6) in bulk powder form, from Portugal
The tariff classification of Ruxolitinib Phosphate (CAS No. 1092939-17-7) in bulk powder form, from Taiwan
The tariff classification of Trilaciclib Dihydrochloride (CAS No. 1977495-97-8) and Ruxolitinib Phosphate (CAS No. 1092939-17-7) in bulk form, from Taiwan
The tariff classification of Vibegron (CAS No. 1190389-15-1) in bulk form, from India
The tariff classification of Vericiguat (CAS No. 1350653-20-1) in bulk form and Verquvo® Tablets in dosage form, from Germany
The tariff classification of Sitagliptin Phosphate Monohydrate (CAS No. 654671-77-9) in bulk form, from Spain
The tariff classification of Bicalutamide (CAS No. 90357-06-5), Linagliptin (CAS No. 668270-12-0) and Aripiprazole (CAS No. 129722-12-9) in bulk powder form, from India
The tariff classification of Imatinib (CAS No. 152459-95-5) and Tofacitinib Citrate (CAS No. 540737-29-9) in bulk powder form, from Italy
The tariff classification of VITRAKVI™ capsules in dosage form and Larotrectinib (CAS No. 1223403-58-4) in bulk form, from the United States and imported from the United Kingdom
The tariff classification of Sitagliptin Phosphate Monohydrate (CAS No. 654671-77-9), Spironolactone (CAS No. 52-01-7) and Ticagrelor (CAS No. 274693-27-5) in bulk form, from India
Searching CBP rulings the smart way
TariffLens semantically searches all 200,000+ CBP rulings, surfaces the ones that actually match your product, and builds defensible classifications backed by ruling citations.
Book a demo →